Subscribe
shutterstock_1515410126_mark_van_scyoc-1
Mark Van Scyoc / Shutterstock.com
19 January 2021AmericasMuireann Bolger

USITC to probe alleged engineered-rice theft by Chinese company

The US International Trade Commission (ITC) is to investigate allegations that a Chinese company infringed patents held by Ventria Bioscience by importing genetically-engineered rice seeds for medical purposes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
US company secures genetically modified rice ban against Chinese rival
15 September 2022   Kansas-based company wins block on infringing plant-based albumins | Genetically programmed rice expresses human proteins used in immunotherapy drugs, gene therapies and vaccines.
Big Pharma
UPDATED: ITC blocks Chinese imports of rice-derived rHSA products after ALJ review
20 October 2022   Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice.
Americas
USITC launches drug research patents probe
28 November 2022   German biopharma company’s complaint against Palo Alto competitor prompts commission to investigate | Patents in dispute relate to bio-layer interferometry.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
US company secures genetically modified rice ban against Chinese rival
15 September 2022   Kansas-based company wins block on infringing plant-based albumins | Genetically programmed rice expresses human proteins used in immunotherapy drugs, gene therapies and vaccines.
Big Pharma
UPDATED: ITC blocks Chinese imports of rice-derived rHSA products after ALJ review
20 October 2022   Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice.
Americas
USITC launches drug research patents probe
28 November 2022   German biopharma company’s complaint against Palo Alto competitor prompts commission to investigate | Patents in dispute relate to bio-layer interferometry.

More on this story

Biotechnology
US company secures genetically modified rice ban against Chinese rival
15 September 2022   Kansas-based company wins block on infringing plant-based albumins | Genetically programmed rice expresses human proteins used in immunotherapy drugs, gene therapies and vaccines.
Big Pharma
UPDATED: ITC blocks Chinese imports of rice-derived rHSA products after ALJ review
20 October 2022   Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice.
Americas
USITC launches drug research patents probe
28 November 2022   German biopharma company’s complaint against Palo Alto competitor prompts commission to investigate | Patents in dispute relate to bio-layer interferometry.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?